secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001999480-24-000040
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q3 net loss $16.8M; ALTO-100 fails Phase 2b MDD primary endpoint
--------------------------------------------------------------------------------

- Net loss of $16.8M in Q3 2024 vs $9.1M a year ago; R&D expense $13.1M, G&A $5.8M.
- Cash, cash equivalents & restricted cash ~$182M expected to fund operations into 2027.
- ALTO-100 Phase 2b MDD missed primary endpoint; biomarker-positive mITT (n=196) not significant.
- Adjunctive subgroup (n=61) showed clinically meaningful effect (Cohen's d=0.47, p=0.09); no MDD advancement planned.
- Timelines: ALTO-300 & ALTO-203 topline 1H 2025; ALTO-101 topline 2H 2025; ALTO-100 bipolar depression topline 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/0001999480-24-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/alto-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001999480-24-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer